BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 19247656)

  • 21. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.
    Viguier J; Boige V; Miquel C; Pocard M; Giraudeau B; Sabourin JC; Ducreux M; Sarasin A; Praz F
    Clin Cancer Res; 2005 Sep; 11(17):6212-7. PubMed ID: 16144923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients.
    Goekkurt E; Hoehn S; Wolschke C; Wittmer C; Stueber C; Hossfeld DK; Stoehlmacher J
    Br J Cancer; 2006 Jan; 94(2):281-6. PubMed ID: 16317430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.
    Liu D; O'Day SJ; Yang D; Boasberg P; Milford R; Kristedja T; Groshen S; Weber J
    Clin Cancer Res; 2005 Feb; 11(3):1237-46. PubMed ID: 15709194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adenosine diphosphate ribosyl transferase and x-ray repair cross-complementing 1 polymorphisms in gastric cardia cancer.
    Miao X; Zhang X; Zhang L; Guo Y; Hao B; Tan W; He F; Lin D
    Gastroenterology; 2006 Aug; 131(2):420-7. PubMed ID: 16890595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. XRCC1 Arginine194Tryptophan and GGH-401Cytosine/Thymine polymorphisms are associated with response to platinum-based neoadjuvant chemotherapy in cervical cancer.
    Kim K; Kang SB; Chung HH; Kim JW; Park NH; Song YS
    Gynecol Oncol; 2008 Dec; 111(3):509-15. PubMed ID: 18851872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma.
    Stocker G; Ott K; Henningsen N; Becker K; Hapfelmeier A; Lordick F; Hois S; Plaschke S; Höfler H; Keller G
    Eur J Cancer; 2009 Dec; 45(18):3326-35. PubMed ID: 19822419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy.
    Ruzzo A; Graziano F; Kawakami K; Watanabe G; Santini D; Catalano V; Bisonni R; Canestrari E; Ficarelli R; Menichetti ET; Mari D; Testa E; Silva R; Vincenzi B; Giordani P; Cascinu S; Giustini L; Tonini G; Magnani M
    J Clin Oncol; 2006 Apr; 24(12):1883-91. PubMed ID: 16622263
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
    Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
    Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
    J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients.
    Khrunin AV; Moisseev A; Gorbunova V; Limborska S
    Pharmacogenomics J; 2010 Feb; 10(1):54-61. PubMed ID: 19786980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients.
    Kweekel DM; Gelderblom H; Antonini NF; Van der Straaten T; Nortier JW; Punt CJ; Guchelaar HJ
    Eur J Cancer; 2009 Mar; 45(4):572-8. PubMed ID: 19084393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of DNA repair and xenobiotic pathway gene polymorphisms with genetic susceptibility to gastric cancer patients in West Bengal, India.
    Ghosh S; Ghosh S; Bankura B; Saha ML; Maji S; Ghatak S; Pattanayak AK; Sadhukhan S; Guha M; Nachimuthu SK; Panda CK; Maity B; Das M
    Tumour Biol; 2016 Jul; 37(7):9139-49. PubMed ID: 26768611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The SOD2 Val/Val genotype enhances the risk of nonsmall cell lung carcinoma by p53 and XRCC1 polymorphisms.
    Liu G; Zhou W; Park S; Wang LI; Miller DP; Wain JC; Lynch TJ; Su L; Christiani DC
    Cancer; 2004 Dec; 101(12):2802-8. PubMed ID: 15534883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer.
    Dong M; Nio Y; Yamasawa K; Toga T; Yue L; Harada T
    J Surg Oncol; 2003 Feb; 82(2):111-20. PubMed ID: 12561067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
    Ott K; Rachakonda PS; Panzram B; Keller G; Lordick F; Becker K; Langer R; Buechler M; Hemminki K; Kumar R
    Ann Surg Oncol; 2011 Sep; 18(9):2688-98. PubMed ID: 21347786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between genotype and enzyme activity of glutathione S-transferases M1 and P1 in Chinese.
    Zhong SL; Zhou SF; Chen X; Chan SY; Chan E; Ng KY; Duan W; Huang M
    Eur J Pharm Sci; 2006 May; 28(1-2):77-85. PubMed ID: 16488119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
    Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin.
    Kim JG; Sohn SK; Chae YS; Song HS; Kwon KY; Do YR; Kim MK; Lee KH; Hyun MS; Lee WS; Sohn CH; Jung JS; Kim GC; Chung HY; Yu W
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):355-60. PubMed ID: 19052714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gastric carcinogenesis: Possible role of polymorphisms of GSTM1, GSTT1, and GSTP1 genes.
    Tripathi S; Ghoshal U; Ghoshal UC; Mittal B; Krishnani N; Chourasia D; Agarwal AK; Singh K
    Scand J Gastroenterol; 2008; 43(4):431-9. PubMed ID: 18365908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer.
    Huang ZH; Hua D; Du X; Li LH; Mao Y; Liu ZH; Song MX; Zhou XK
    World J Gastroenterol; 2008 Nov; 14(41):6401-7. PubMed ID: 19009659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.